Outcomes for patients with hematologic malignancy infected with COVID-19 have not been
aggregated. The objective of this study was to perform a systematic review and meta …

Background Patients with coronavirus disease 2019 (COVID-19) who have underlying
malignancy have a higher mortality rate compared with those without cancer, although the …

Patients with chronic lymphocytic leukemia (CLL) have an increased risk for severe COVID-
19 disease and mortality. The goal of this study was to determine the efficacy of COVID-19 …

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a novel virus that spread
worldwide from 2019 causing the Coronavirus disease 19 (COVID-19) pandemic. SARS …

Methods We examined 44 consecutive patients with CLL who received two doses of mRNA
vaccine (BNT162b2 or mRNA-1273) between 1/2/21 and 3/12/21 and were tested for anti …

Patients with chronic lymphocytic leukemia (CLL) have an impaired antibody response to
coronavirus disease 2019 (COVID-19) vaccination. Here, we evaluated the antibody …

Importance SARS-CoV-2 infection has been associated with more severe disease and
death in patients with cancer. However, the implications of certain tumor types, treatments …

B-cell chronic lymphocytic leukaemia (CLL) is associated with immunosuppression and
patients are at increased clinical risk following SARS-CoV-2 infection. Covid-19 vaccines …

Patients with chronic lymphocytic leukemia (CLL) have a suboptimal humoral response to
vaccination. Recently, BNT162b2, an mRNA COVID-19 vaccine with a high efficacy of 95 …

SARS-CoV-2 is the virus responsible for the COVID-19 pandemic. COVID-19 has highly
variable disease severity and a bimodal course characterized by acute respiratory viral …